Excerpt: "
Jay Lalezari: Absolutely. The first order of business is for us to prospectively confirm what we've seen retrospectively. When we do that, it's a game-changer for CytoDyn. I think it's a game-changer for patients with CCR5-positive solid tumors. And at that point, we've spoken to quite a number of the pharmaceutical entities that have checkpoint assets, and they're really just waiting to see us confirm this signal prospectively before diving in, because it gives them an opportunity, not only will patients benefit, but it'll give the companies an opportunity to vastly expand their markets.

Karen Jagoda: Yes, I've always wondered about the drug manufacturers who are designing these drugs that don't work for a small portion of the population. So I'm just guessing this would open up a much broader range of patients that they could help. So that's also part of the mission here, right?

It's not to reinvent the wheel, but to make what's already out there just more effective for more people.

Lalezari: Absolutely. As I said, checkpoint inhibitors are very effective in patients who are candidates for them. The problem is, as you said, most patients are not candidates, and pharma has been working for years trying to figure out how to convert these cold tumor environments to hot. So what CytoDyn has stumbled into is that's why I use the word paradigm shift. It really is a game-changer, potentially in solid tumor oncology."

Very encouraging words.